# Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts

> **NCT06491446** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Antiva Biosciences** · enrollment: 141 (actual)

## Conditions studied

- Human Papillomavirus Infection

## Interventions

- **DRUG:** ABI-2280

## Key facts

- **NCT ID:** NCT06491446
- **Lead sponsor:** Antiva Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-27
- **Primary completion:** 2025-10-16
- **Final completion:** 2026-06-30
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491446, "Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06491446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*